This implies that when modelling OS in MM using BCR to treatment, there is little statistical power to distinguish a patient who experiences Stable Disease versus Progressive Disease or who experiences Partial Response versus Minimal Response to LoT 1 / ASCT. The gene discussed is BCR; the disease is Miyoshi myopathy.